Navigating the FDA's Guidelines on Off-Label Promotions
Watch the Course Now
Watch the Course Now
About the Course
FDA oversight of prescription drug and medical device labeling and advertising continues to shape how manufacturers communicate scientific and medical information to healthcare professionals. Distributing publications that reference unapproved uses of approved or cleared products can create regulatory exposure when communication practices fall outside current FDA expectations. Organizations involved in promotional review, medical affairs, and scientific dissemination must distinguish between permissible scientific exchange and promotional activity that may trigger agency scrutiny.
The course addresses the FDA’s current policy on distributing scientific and medical references containing off-label information, along with applicable statutes, regulatory requirements, monitoring activities, and untitled letter analysis. Attention is also given to publication practices, avoidable compliance mistakes, and internal measures that support consistent communication standards. The material is structured for organizations seeking practical direction on reducing enforcement risk while maintaining appropriate scientific and medical communications involving approved drugs and cleared medical devices.
Key Areas Covered
Quality training, expert insights, and answers that matter. Know your Expert
Ready to Strengthen Your Team? Let’s Build Your Training Plan.
Your team deserves the clarity.
Your organization deserves the confidence.
Upcoming Courses
Your TalkFDA Webinar Experience
1. Confirmation
3. Access course materials
4. Watch The Streaming and Complete your Course


